Payment overview · 2025
General Payments
$459.90
18 reported records · 10 companies
Healthcare provider profile · identity verified
Jaskeerit Kaur Purewal, MD
Allopathic & Osteopathic Physicians|Family Medicine · WESTLAKE VILLAGE, CA · NPI 1497251672
Verified facts
What the public records show
CMS Open Payments records show Jaskeerit Kaur Purewal, MD received $459.90 in general payments during 2025 across 18 reported records.
Gilead Sciences, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $101.08 | 22.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.94 | 12.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.75 | 12.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.59 | 10.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.82 | 8.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.73 | 8.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.90 | 8.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.00 | 7.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.82 | 6.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.27 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.90 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $72.82 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.94 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.59 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 102 |
| Lisinopril | Lisinopril | 242 | 89 |
| Losartan Potassium | Losartan Potassium | 214 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 82 |
| Gabapentin | Gabapentin | 148 | 63 |
| Metformin Hcl | Metformin Hcl | 143 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 60 |
| Omeprazole | Omeprazole | 116 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 47 |
| Alendronate Sodium | Alendronate Sodium | 85 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 29 |
| Furosemide | Furosemide | 76 | 34 |
| Trazodone Hcl | Trazodone Hcl | 71 | 26 |
| Pregabalin | Pregabalin | 62 | 13 |
| Donepezil Hcl | Donepezil Hcl | 61 | 17 |
| Spironolactone | Spironolactone | 60 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Simvastatin | Simvastatin | 56 | 18 |
| Famotidine | Famotidine | 50 | 25 |
| Jardiance | Empagliflozin | 49 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 22 |
| Meloxicam | Meloxicam | 48 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 11 |
| Eliquis | Apixaban | 47 | 17 |
| Alprazolam | Alprazolam | 46 | 19 |
| Ezetimibe | Ezetimibe | 45 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 15 |
| Chlorthalidone | Chlorthalidone | 43 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 16 |
| Mirtazapine | Mirtazapine | 42 | 12 |
| Potassium Chloride | Potassium Chloride | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 19 |
| Sertraline Hcl | Sertraline Hcl | 41 | 15 |
| Ibuprofen | Ibuprofen | 38 | 18 |
| Montelukast Sodium | Montelukast Sodium | 38 | 17 |
| Metformin Hcl Er | Metformin Hcl | 37 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Azelastine Hcl | Azelastine Hcl | 36 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 13 |
| Atenolol | Atenolol | 32 | suppressed |
| Estradiol | Estradiol | 32 | 13 |
| Fenofibrate | Fenofibrate | 32 | 14 |
| Allopurinol | Allopurinol | 30 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 15 |
| Carvedilol | Carvedilol | 24 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Prednisone | Prednisone | 21 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | 13 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 13 |
| Nystatin | Nystatin | 17 | 11 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 12 |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.90 · 18 records | Gilead Sciences, Inc. | AIRSUPRA, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, OTEZLA, PROLIA, REPATHA, REXULTI, SHINGRIX, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error